FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)													
1. Name and Address of Reporting Person* Chow Gregory K.					2. Issuer Name and Ticker or Trading Symbol Aptose Biosciences Inc. [APTO]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105					3. Date of Earliest Transaction (Month/Day/Year) 07/10/2020						X Officer (give title below) Other (specify below) Executive VP & CFO				
TORONTO, A6 M2J 4R3				4. I	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqu							osed of, or I	Beneficially	Owned	
(Instr. 3) Date			2. Transaction Date (Month/Day/Ye	ar) Exe	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Beneficially Owned Following Reported Transaction(s)			Form:	7. Nature of Indirect Beneficial
			(M	Code		V	Amoun	(A) or (D)	Price	(Instr. 3 a	or I		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common	Shares		07/10/2020			S		126,66	58 D	\$ 6.05	232,846			D	
			Table I		vative Securiti	es Acquire	ed, Di	sposed o	f, or Ben	eficial		OIND COIN	ioi numbe		
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Y	3A. Deem Execution any	(e.g., ed Date, if	4. Transaction Code (Instr. 8)	es Acquire	cont the f ed, Di tions, 6. Do	ained ir orm dis sposed o	of, or Bendible securities of the securities of	eficiallrities) 7. Ti Amo	not requ ntly valid		9. Number Derivative Securities Beneficially Owned Following	of 10. Owners: Form of Derivati Security Direct (1)	Ownership (Instr. 4)
						(A) or Disposed of (D) (Instr. 3, 4, and 5)							Reported Transaction (Instr. 4)	or Indir (I) (Instr. 4	
					Code V	(A) (D)	Date Exer		Expiration Date	¹ Title	Amount or Number of Shares				
Repor	ting O	wners													
					Relationships										
Reporting Owner Name / Address Direct				rector	or 10% Officer				Other						

Executive VP & CFO

Signatures

Chow Gregory K.

TORONTO, A6 M2J 4R3

/s/ Janet Clennett as attorney-in-fact for Gregory K. Chow	07/10/2020		
**Signature of Reporting Person	Date		

Owner

Explanation of Responses:

C/O APTOSE BIOSCIENCES INC.

251 CONSUMERS ROAD, SUITE 1105

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of 225,000 restricted stock units, previously reported on a Form 4/A filed with the Securities and Exchange Commission on March 10, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.